Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session on the role of subcutaneous tocilizumab in managing rheumatoid arthritis.
Immunological pathways play a crucial role in disease management, especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
Tocilizumab is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody basically administered through intravenous infusion every 4 weeks. The treatment has been approved for patients with rheumatoid arthritis.
Due to the low risk of immunogenicity, the flexibility of IV and SC administration, and the convenience of administering weekly once, tocilizumab provides an effective treatment for severe, active, and progressive RA in adults.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
2.
Research uncovers hidden Australian skin cancer epidemic
3.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
4.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
5.
The American College of Physicians updated its recommendations for colorectal cancer screening.
1.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation